141 related articles for article (PubMed ID: 21156460)
1. Ten years of improvement in the management of multiple myeloma: 2000-2010.
Harousseau JL
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):424-42. PubMed ID: 21156460
[TBL] [Abstract][Full Text] [Related]
2. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches to the management of myeloma.
Rajkumar SV
Oncology (Williston Park); 2005 Apr; 19(5):621-5. PubMed ID: 15948290
[TBL] [Abstract][Full Text] [Related]
4. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
5. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Lonial S; Cavenagh J
Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
[TBL] [Abstract][Full Text] [Related]
6. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
7. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
8. The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
Joks M; Jurczyszyn A; Machaczka M; Skotnicki AB; Komarnicki M
Eur J Haematol; 2015 Feb; 94(2):109-14. PubMed ID: 25039659
[TBL] [Abstract][Full Text] [Related]
9. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Nishihori T; Alsina M
Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
[TBL] [Abstract][Full Text] [Related]
10. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
11. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
Kumar S
Curr Hematol Malig Rep; 2011 Jun; 6(2):104-12. PubMed ID: 21394431
[TBL] [Abstract][Full Text] [Related]
12. Role of consolidation therapy in transplant eligible multiple myeloma patients.
Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
[TBL] [Abstract][Full Text] [Related]
13. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Palumbo A; Avonto I; Bruno B; Falcone A; Scalzulli PR; Ambrosini MT; Bringhen S; Gay F; Rus C; Cavallo F; Falco P; Massaia M; Musto P; Boccadoro M
Clin Lymphoma Myeloma; 2006 May; 6(6):475-7. PubMed ID: 16796778
[TBL] [Abstract][Full Text] [Related]
15. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
16. Role of consolidation/maintenance therapy in multiple myeloma.
Palumbo A; Mina R; Cerrato C; Cavallo F
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S349-54. PubMed ID: 24290220
[TBL] [Abstract][Full Text] [Related]
17. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
Silvennoinen R; Kairisto V; Pelliniemi TT; Putkonen M; Anttila P; Säily M; Sikiö A; Opas J; Penttilä K; Kuittinen T; Honkanen T; Lundán T; Juvonen V; Luukkaala T; Remes K
Br J Haematol; 2013 Feb; 160(4):561-4. PubMed ID: 23206270
[No Abstract] [Full Text] [Related]
18. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
[TBL] [Abstract][Full Text] [Related]
19. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Yaqub S; Ballester G; Ballester O
Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815
[TBL] [Abstract][Full Text] [Related]
20. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
